NCT06914037

A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies

A Phase 1, Open-Label, Single-Arm Study of the Safety, Pharmacokinetics and Efficacy of CHT101 in Subjects With Relapsed or Refractory T or B Cell Hematological Malignancies

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (estimated)
• Sponsor: Tianjin Medical University Cancer Institute and Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Evaluate the Safety, Pharmacokinetics and Efficacy of CHT101 in Subjects With Relapsed or Refractory T or B Cell Hematological Malignancies

Detailed description

3 planned dose cohorts will be evaluated during dose escalation phase. The dose expansion will be initiated after SRC (safety review committee) reviewing available safety, PK and preliminary efficacy data.

Conditions

• Peripheral T-cell Lymphoma
• Cutaneous T-cell Lymphoma (CTCL)
• NHL (Non-Hodgkin Lymphoma)

Interventions

Type	Name	Description
DRUG	CHT101	CD70 UCAR-T

Timeline

• Start date: 2025-03-31
• Primary completion: 2028-03-31
• Completion: 2028-03-31
• First posted: 2025-04-06
• Last updated: 2025-04-06

Locations

1 site across 1 country: China